Japan
· Delayed Price · Currency is JPY GNI Group Company Description
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia.
GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 867 |
| CEO | Ying Luo |
Contact Details
Address: Nihonbashi-Honcho YS Building Tokyo, 103-0023 Japan | |
| Phone | 81 3 6214 3600 |
| Website | gnipharma.com |
Stock Details
| Ticker Symbol | 2160 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3386370005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ying Luo | Chief Executive Officer |
| Toshiya Kitagawa | Chief Financial Officer |
| Sekitani Kazuki | Chief Operating Officer |